Ymmunobio AG, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, has appointed Michel Janicot, PhD, as its Chief Development Officer (CDO). The CDO role is a new position in which Dr. Janicot will leverage his more than 30 years’ experience in the pharmaceutical industry for Ymmunobio’s development and R&D efforts.
“We are pleased to welcome Dr. Janicot to our growing company,” said Ymmunobio Founder and CEO Katrin Rupalla. “His expertise and insights provide a great benefit in advancing our preclinical development programs for our lead antibodies.”
“I am excited to join this dynamic company, which is making significant progress in how we develop cancer therapies that are more effective and potentially far less toxic than those currently available,” said Dr. Janicot.
Dr. Janicot has deep experience in the pharmaceutical industry, having worked in preclinical development in oncology at organizations that include Rhone-Poulenc Rorer and Johnson & Johnson, in addition to a range of small to midsize biotechnology companies, academic laboratories, and government organizations. He holds a PhD in Biochemistry from the University of Paris VII.
Most recently, Dr. Janicot has been the Founder and Managing Director of JMi ONConsulting, which provides strategic, scientific and operational R&D project management, including leadership for preclinical and drug development.
Investor Relations: Dr. Katrin Rupalla, [email protected]
Ymmunobio AG is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation. Learn more on Ymmunobio’s website and follow on LinkedIn.